Propath (UK)
Propath (UK) is recorded as a service provider in 6 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 6 of 6 trials · Latest update first
A Phase 2, Randomized, Open-label, Platform Study Using a Master Protocol to Evaluate Novel Immunotherapy Combinations as First-Line Treatment in Participants with Recurrent/Metastatic PD-L1-Positive Squamous Cell Carcinoma of the Head and Neck
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
Open label, non-randomized, Phase 1b/2 trial investigating the safety, tolerability, and antitumor activity of S095029 (anti-NKG2A antibody) as a part of combination therapy in participants with locally advanced and unresectable or metastatic MSI-H/dMMR gastro-esophageal junction/gastric cancer
Sponsor Institut De Recherches Internationales Servier IRIS
- Start (EU)
- Latest update
- Estimated end
An Open-Label, Single Agent, Phase I/II Trial Investigating the Safety and Efficacy of RVU120 (SEL120) in Patients with Relapse / Refractory Metastatic or Advanced Solid Tumors
Sponsor Ryvu Therapeutics S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available2 trial-level findings · Read insights
- The trial involved seven principal investigators across Spain and Poland.
- Following review of Part 1 preliminary efficacy data and the overall development program, the sponsor proceeded only with Part 2 Group E, including the food-effect substudy; the Part 2 efficacy-expansion groups were not initiated.
These findings describe the trial, not the service provider’s performance or responsibility.
A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer
Sponsor Glaxosmithkline Research & Development Limited
- Start (EU)
- Latest update
- Estimated end
A Phase 1b/2, multicenter, open-label platform study of select immunotherapy combinations in adult participants with previously untreated advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression
Sponsor Institut De Recherches Internationales Servier IRIS
- Start (EU)
- Latest update
- Estimated end
Phase 1-2 Study of the Safety, Pharmacokinetics, and Preliminary Activity of ASTX660 in Subjects with Advanced Solid Tumors and Lymphomas
Sponsor Taiho Oncology Inc.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Propath (UK)?
The 2026-10-09 snapshot links Propath (UK) to 6 distinct CTIS trials. Recorded services include Laboratory services, Large Panel IF and PDL1 status by IHC, Large Panel IF, HLA-E and PDL-1 expression by HIC in tumour biopsy, pharmacodynamic biomarkers: plasma cytokines and pSTAT proteins analysis. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Propath (UK)?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Gastroenterology, Otolaryngology. Recorded phases include Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Propath (UK) conducted?
The linked trials record locations in 16 countries, including Spain, Italy, Poland, Germany, France. These are trial locations, not confirmed office locations or countries where Propath (UK) delivered services.
What can this page tell me about Propath (UK)'s trial experience?
Browse 6 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Propath (UK). Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Propath (UK) Limited